Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
Baiyu to receive $70 million upfront, with potential for up to $1.1 billion in development, regulatory and commercial milestones as well as tiered royalties.
Unauthorized reproduction is strictly prohibited!